

*Neuropathological investigations of
three murine models of Huntington's
disease*

A thesis presented for the degree
of


Doctor of Philosophy,
University of London

Aysha S. Raza Bsc. (Hons)
2009



UNIVERSITY COLLEGE LONDON
Department of Anatomy and Developmental Biology
Neurodegeneration Research Group

*This thesis is dedicated to the memory of S.M.Jamil-ur Rahman,
who was the greatest advocate of a 'good English education.'*



I Aysha S Raza, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm this has been indicated in this thesis.



“I am just beginning to discover the difficulty of expressing one’s ideas on paper. As long as it consists solely of descriptions it’s pretty easy; but when reasoning comes into play, to make a proper connection, a clearness and a moderate fluency, is to me as I have said, a difficulty of which I had no idea.”

Charles Darwin near the end of the voyage of HMS Beagle

Abstract

Huntington's disease (HD) is a purely genetic neurodegenerative disorder affecting approximately 1 in 10,000 people. It is most commonly associated with excessive involuntary movement, or chorea, combined with varying degrees of other motor, psychiatric and cognitive disturbances. Identification of the mutation in the HD gene prompted the generation of several transgenic mouse models. HD is but one of a family of at least 9 triplet repeat disorders, all of which exhibit protein aggregation by a similar mechanism. The understanding of one disease is therefore of importance to the understanding of them all. This thesis aims to be a comprehensive comparative study of three very different mouse models of HD elucidating the pathological changes that precede and accompany the disease process.

The work described in this thesis presents a detailed account of a longitudinal study of the pathological changes that occur within the brains of founder generations of mice transgenic for exon 1 of the HD gene, containing a highly expanded CAG repeat, the R6 lines. I have determined the intracellular sites for deposition and accumulation of the mutant protein huntingtin (*htt*), within both the neurons and glia of the central nervous system. The progressive accumulation of additional proteins within these aggregates has been described. The temporal evolution and spatial distribution of the neuronal intranuclear inclusion (NII) was determined using both immunohistochemical and morphometric analyses. The cellular consequences resulting from the aggregation of mutant *htt* were also investigated. I have conducted a detailed morphometric analysis of neurones within the *cerebral cortex*, *striatum* and *cerebellum* throughout the period of protein deposition, until the eventual degeneration of these cells. The dendritic and somal changes resulting from the cellular disruption associated with these NII are also described.

In a further series of experiments I have investigated the changes that occur in a novel model of HD, namely the conditional, doxycycline inducible double transgenic mouse, HD94 model. It was interesting to find that the same construct when differently manipulated in two mouse lines can produce such contrasting symptoms and pathology. This was highlighted by the comparison of immunohistochemical and morphometric analyses between the HD94 and the R6 lines, where the pattern of mutant protein deposition was found to vary significantly.

Lastly I have studied a more genetically accurate murine model of HD, the HD80 'knock-in model'. These mice develop a pathology broadly similar to that of the R6 lines but markedly different to that of the HD94, and over a much longer time frame

This detailed comparative analysis of the molecular and cellular pathology of three transgenic mouse models of HD provides new insights identifying novel and unique neuropathology and suggests new approaches for therapeutic treatments for this disease.

Acknowledgements

I must thank a lot of people whose roles have been vital in the long gestation of this thesis, and who are far too many to name individually. However I am enormously indebted to my supervisor Stephen Davies who has seen me through the pain barrier and I am grateful for his advice and friendship and it has been a real honour to know and work with such a gifted scientist. Grateful thanks go also to Jon Clarke for agreeing to be my second supervisor. Very special thanks to Mark Turmaine for advice on all things EM and for his friendship. And thanks are also due to Elizabeth Slavik-Smith² for advice on all things nuclear and shoes.

This PhD would not have been possible without the mouse models for which I am obliged to; Gillian Bates, Laura Mangiarini and Ben Woodman for the endless supply of the R6 mice, Peggy Shelbourne for her knock-in mice and Ai Yamamoto for her conditional mouse model and great times in New York. I would like also to thank the Huntington's Disease Society of America for funding this PhD, as well as the Hereditary Disease Foundation, The Wellcome Trust and The Bogue Fellowship for small sums of money over a very long time.

Heartfelt thanks to Susan Evans for taking a chance and putting me on the road to science and for keeping me rooted in the big picture. Yvonne DeVille for being the best listener and helping me to maintain some semblance of sanity towards the end. Wendy Birch for being the best distraction from work ever, and whose friendship means a lot to me.

Thanks also to my family who have supported me through my education and helped make this a far more challenging experience than it needed to be!

I must also thank my Openlab elves Adil Raza and Jenny Parker who spent weeks measuring things instead of getting up to no good in their summer holidays! I am indebted to the late great Brian Ruth and 'Mac' Mike Corder for bailing me out of every misbehaving computer episode of which there have been many!

Finally I would like to thank the members of the lab, past, present and future, the good, bad and ugly all of whom have made the lab a colourful place to work in and who made it a character-building experience, hopefully one that has left me a better more patient person! I wish them all well in their own research projects and thank them for helping the evolution of mine.

And thanks inevitably to the fluffy people without whom there would be no thesis to quote Walt Disney: 'I only hope that we never lose sight of one thing- that it was all started by a mouse'. 🐭

Contents

Dedication.....	i
Quote from Darwin.....	ii
Abstract.....	iii
Acknowledgements.....	iv
Contents.....	v
Figures.....	viii
Abbreviations.....	xiii

I. Introduction:

Chapter 1:Introduction.....	1
1.1.Historical background.....	3
1.2.Epidemiology.....	4
1.3.Aetiology.....	4
1.4.Disease symptoms.....	5
1.5.Current therapies.....	7
1.6.Pathology.....	8
1.7.The HD gene mutation.....	12
1.8.Consequences of (CAG)n in HD.....	14
1.9.Huntingtin.....	16
1.9.1.Normal huntingtin.....	17
1.9.2.Abnormal huntingtin.....	17
1.10.Trinucleotide repeat diseases.....	18
1.11.Disease model systems.....	19
1.12.Current theories of HD pathogenesis.....	22
1.12.1.Protein aggregation.....	22
1.12.2.Seeding aggregation theory.....	23
1.12.3.Polar zipper theory.....	23
1.12.4.The NII.....	24
1.12.5.The DNI.....	28
1.12.6.Cell damage control:The UPS system.....	29
1.12.7.Cell death.....	33
1.12.8.Glial response to the presence of NIIs.....	35
1.13.Aims of this study.....	36

II. Materials and methods:

Chapter 2:Materials and methods.....	37
2.1.Transgenic mouse models.....	38
2.1.1.Mangiarini/Bates Transgenic R6 Models.....	40
2.1.2.Yamamoto HD94 Conditional Model.....	44
2.1.3.Shelbourne Knock-in Model.....	47
2.2.Tissue processing for light microscopy.....	49
2.3.Tissue processing for electron microscopy.....	49

2.4.Immunocytochemistry.....	50
2.5.Morphometry.....	52
2.6.Golgi impregnation.....	53
2.6.1.Rapid “single section” Golgi.....	53
2.6.2.Golgi-Cox method.....	54
2.6.3.Golgi analysis.....	56

III. Results:

Chapter 3: The nature of the Inclusion.....	59
3.1.Mangiarini/Bates Transgenic R6 Models.....	59
3.2.Yamamoto HD94 Conditional Model.....	68
3.3.Shelbourne Knock-in Model.....	74
3.4.Summary of results.....	78
Chapter 4: Immunocytochemical investigations.....	83
4.1.Mangiarini/Bates Transgenic R6 Model.....	83
4.1.1.Molecular components.....	83
4.1.2.Regional sequential patterns.....	86
4.1.3.Temporal sequential patterns.....	96
4.2.Yamamoto HD94 Conditional Model.....	101
4.2.1.Regional sequential patterns.....	101
4.2.2.Temporal sequential patterns.....	103
4.3.Shelbourne Knock-in Model.....	105
4.3.1.Regional sequential patterns.....	106
4.3.2.Temporal sequential patterns.....	110
4.4.Summary of results.....	113
Chapter 5: Morphometric Studies.....	115
5.1.Mangiarini/Bates Transgenic R6 Models.....	116
5.2.Yamamoto HD94 Conditional Model.....	123
5.3.Shelbourne Knock-in Model.....	126
5.4.Summary of results.....	129
Chapter 6: Golgi Studies.....	133
6.1.Mangiarini/Bates Transgenic R6 Models.....	135
6.1.1.Striatal pathology.....	136
6.1.1.1.Dendritic arbors.....	136
6.1.1.2.Diameters of dendritic shafts.....	139
6.1.1.3.Spine density.....	142
6.1.1.4.Spine morphology & abnormal dendritic growths.....	143
6.1.2.Giant cholinergic neurones.....	145
6.1.3.Cortical pathology.....	146
6.1.4.Hippocampal cell pathology.....	147
6.1.5.Purkinje cell pathology.....	148
6.1.6.Glia.....	149
6.1.7.Olfactory bulbs.....	150
6.2.Yamamoto HD94 Conditional Model.....	151
6.2.1.Striatal pathology.....	151
6.2.1.1.Dendritic arbors.....	151
6.2.1.2.Diameters of dendritic shafts.....	152
6.2.1.3.Spine density.....	154
6.3.Shelbourne Knock-in Model.....	156
6.3.1.Striatal pathology.....	156

6.3.1.1.Dendritic arbors.....	157
6.3.1.2.Diameters of dendritic shafts.....	158
6.3.1.3.Spine density.....	160
6.4.Summary of results.....	161
Chapter 7:Neuronal Death Processes.....	168
7.1.Mangiarini/Bates Transgenic R6 Models.....	171
7.2.Yamamoto HD94 Conditional Model.....	180
7.3.Shelbourne Knock-in Model.....	184
7.4.Summary of results.....	190
Chapter 8:Glial Observations.....	193
8.1.Mangiarini/Bates Transgenic R6 Models.....	193
8.2.Yamamoto HD94 Conditional Model.....	201
8.3.Shelbourne Knock-in Model.....	205
8.4.Summary of results.....	209
IV. Discussion:	
Chapter 9: Discussion.....	213
9.1. Huntingtin aggregation in the nucleus and the formation of an NII.....	214
The NII & the DNI.....	217
9.2. Continued accumulation of Huntingtin protein.....	218
The Clastosome & the Aggresome.....	221
9.3. Cachexia, Sarcopaenia & Neuronal shrinkage.....	224
9.4. Neuronal Atrophy and dendritic remodelling.....	230
9.5. Dark cell degeneration.....	241
Apoptosis in HD.....	242
Autophagy & autophagic cell death.....	245
V Conclusion:	
Chapter 10: Conclusions.....	249
10.1.Conclusions drawn from this study.....	250
10.2.Further Studies.....	252
Appendices:.....	253
Appendix 1: Legend for brain sections used in this thesis.....	254
Appendix 2: Summary timeline of the R6/2 model.....	257
Appendix 3: Summary timeline of the R6/1 model.....	258
Appendix 4: Summary timeline of the HD94 model.....	259
Appendix : Summary timeline of the HD80 model.....	260
.	
References:.....	261
List of references.....	262

List of Figures & Tables

Chapter 1: Introduction

Figure 1: George Huntington aged 24 when he wrote his landmark paper.....	2
Figure 1.1: HD brain pathology from Harper.....	8
Figure 1.2: Grades of HD brain from Bird.....	9
Figure 1.3: The HD gene from Gusella <i>et al.</i> 1996.....	13
Figure 1.4: Phenotype in relation to CAG repeat size.....	14
Figure 1.5: Variability in age of onset in relation to CAG repeat size.....	16
Figure 1.6: Variability in the age of onset in relation to CAG repeat sizes in poly Q diseases..	16
Table 1.1: Trinucleotide repeat diseases.....	18
Figure 1.7: Max Perutz and the structural model of the polar zipper.....	24
Figure 1.8: Electron micrographs showing the nature of the NII.....	25
Figure 1.9: The NII as seen at light microscopy level.....	26
Figure 1.10: Electron micrographs and light microscopy photos of the DNI.....	29
Figure 1.11: Schematic diagram of the proteasome.....	30
Figure 1.12: Schematic diagram of the ubiquitin proteasome system.....	31
Figure 1.13: Schematic diagram of protein management systems in the cell.....	32

Chapter 2: Materials and methods

Figure 2.1: Diagram of the constructs of all the R6 lines of murine model.....	40
Figure 2.2: Simplified construct of the R6/2 model.....	40
Figure 2.3: Photographs of R6/2 and control mice.....	43
Figure 2.4: Photographs of R6/2 and control mice in tail suspension/clasping test.....	43
Figure 2.5: Simplified construct of the HD94 model.....	45
Figure 2.6: Diagram explaining the DOX system used in the HD94 model.....	48
Figure 2.7: Photographs of HD94 mice in tail suspension/clasping test.....	46
Figure 2.8: Schematic diagram of how the HD80 mice were constructed.....	47
Table 2.1: Table of all the primary anti <i>htt</i> antibodies used.....	51
Table 2.2: Table of all the primary antibodies used in this study.....	51
Figure 2.9: Diagram explaining the Sholl analysis.....	57
Figure 2.10: Diagram explaining how branch orders were determined.....	57

Chapter 3: The Nature of the Inclusion

Figure 3.1: Drawing of the evolution of the inclusion in the neurone.....	59
Figure 3.2: Characterisation scale for inclusion evolution.....	60
Figure 3.3: Comparative immunostaining of <i>htt</i> in the R6/2 and R6/1 models.....	61
Figure 3.4: Graphs of cortical and striatal NII and somal areas in R6/2 brains.....	63
Figure 3.5: Graphs of cortical and striatal NII and somal areas in R6/1 brains.....	65
Figure 3.6: Graphs of volumes and surface areas in R6/2 model.....	66
Figure 3.7: Graphs of volumes and surface areas in R6/1 model.....	66
Figure 3.8: EM48 stained NII and DNI in the <i>striatum</i> of the R6/2 model at EM.....	67
Figure 3.9: Inclusions in the HD94 model at LM.....	68
Figure 3.10: EM48 stained DNIs in the <i>striatum</i> of the HD94 model.....	69

Figure 3.11: Montage of huge inclusions seen in HD94 model.....	69
Figure 3.12: Comparative photos of inclusions in HD94 and R6/2 models.....	70
Figure 3.13: Comparative immunostaining of <i>htt</i> in the HD94 model.....	71
Figure 3.14: An NII in a toluidine blue stained semi thin section of HD94 <i>cortex</i>	71
Figure 3.15: Graph of cortical DNI area variation in the HD94 model.....	72
Figure 3.16: DNIs in the <i>cortex</i> of HD94 model at EM.....	73
Figure 3.17: Comparative immunostaining of <i>htt</i> antibodies in the HD80 model.....	75
Figure 3.18: Graphs of striatal NII and somal areas in the HD80 model.....	76
Figure 3.19: Inclusions in the HD80 model at LM.....	77
Table 3.1: Comparison of inclusions in all models studies.....	78
Figure 3.20: Comparative graphs of NII area in R6/2, R6/1 and HD80 models.....	79
Figure 3.21: Speculative possible structures of inclusions.....	81

Chapter 4:Immunocytochemical Investigations

Figure 4.1: Regional sequential maps of the R6/2 and R6/1 longitudinal studies.....	87
Figure 4.2: Regional inclusion staining of R6/2 model at 1 week of age.....	88
Figure 4.3: Regional inclusion staining of R6/2 model at 2 weeks of age.....	89
Figure 4.4: Regional inclusion staining of R6/2 model at 3 weeks of age.....	90
Figure 4.5: Regional inclusion staining of R6/2 model at 4 weeks of age.....	91
Figure 4.6: Regional inclusion staining of R6/1 model at 1 month of age.....	93
Figure 4.7: Regional inclusion staining of R6/1 model at 2 months of age.....	93
Figure 4.8: Regional inclusion staining of R6/1 model at 3 months of age.....	94
Figure 4.9: Regional inclusion staining of R6/1 model at 4 months of age.....	95
Figure 4.10: Temporal sequential tables and photos in <i>cortex</i> of the R6/2 model.....	97
Figure 4.11: Temporal sequential tables and photos in <i>cortex</i> of the R6/1 model.....	97
Figure 4.12: Temporal sequential tables and photos in <i>striatum</i> of the R6/2 model.....	98
Figure 4.13: Temporal sequential tables and photos in <i>striatum</i> of the R6/1 model.....	98
Figure 4.14: Temporal sequential tables and photos in <i>cerebellum</i> of the R6/2 model.....	99
Figure 4.15: Temporal sequential tables and photos in <i>cerebellum</i> of the R6/1 model.....	99
Figure 4.16: Regional sequential maps of the HD94	102
Figure 4.17: Regional inclusion staining of HD94 model at 36 weeks of age.....	103
Figure 4.18: Temporal sequential tables and photos of the HD94 model.....	104
Figure 4.19: Regional sequential maps of the HD80 model.....	106
Figure 4.20: Regional inclusion staining of HD80 full length (FL) model.....	108
Figure 4.21: Regional inclusion staining of HD80 fragment (Fr) model.....	109
Figure 4.22: Temporal sequential tables and photos of the HD80 FL at 24 months.....	111
Figure 4.23: Temporal sequential tables and photos of the HD80 Fr at 24 months.....	111
Figure 4.24: Temporal sequential tables and photos of the HD80 FL at 36 months.....	112
Figure 4.25: Temporal sequential tables and photos of the HD80 Fr at 36 months.....	112

Chapter 5:Morphometric Studies

Figure 5.1: Graph showing the loss of body and brain weight.....	115
Figure 5.2: Photographs of R6/2 and control brains.....	116
Figure 5.3: Graphs showing somal areas for neuronal populations in R6/2 model.....	117

Figure 5.4: Graphs of nuclear areas and area/perimeter ratios in <i>striatum</i> of R6/2 model.....	119
Figure 5.5: Graphs showing somal areas for neuronal populations in R6/1 model.....	121
Figure 5.6: Graphs of nuclear areas and area/perimeter ratios in <i>striatum</i> of R6/1 model.....	122
Figure 5.7: Graphs showing somal areas for neuronal populations in HD94 model.....	124
Figure 5.8: Graphs of nuclear areas and area/perimeter ratios in <i>striatum</i> of HD94 model.....	125
Figure 5.9: Graphs showing somal areas for neuronal populations in HD80 model.....	127
Figure 5.10: Graphs of nuclear areas and area/perimeter ratios in <i>striatum</i> of HD80 model.....	128
Figure 5.11: Summary of somal areas results graphs.....	130
Figure 5.12: Summary of nuclear parameter results graphs.....	131

Chapter 6: Golgi Studies

Figure 6.1: Drawings of medium spiny neurones from HD and control brain.....	133
Figure 6.2: Drawings of medium spiny neurones from R6/2 and LMC brain.....	136
Figure 6.3: Graphs of Sholl analyses of the R6/2 model at 4, 8 and 12 weeks of age.....	137
Figure 6.4: Graphs of Sholl analyses of the R6/1 model at 36 weeks/9 months of age.....	138
Figure 6.5: Graphs of dendritic shaft diameters in the R6/2 and R6/1 models.....	139
Figure 6.6: Drawings of dendritic branch segments in the R6/2 model.....	140
Figure 6.7: Drawings of dendritic branch segments in the R6/1 model.....	141
Figure 6.8: Graphs of dendritic spine density in the R6/2 and R6/1 models.....	142
Figure 6.9: Diagram showing different spine morphologies.....	143
Figure 6.10: Drawings showing different dendritic morphologies in the R6/2 model.....	144
Figure 6.11: Drawings showing giant cholinergic neurones in the R6/2 model.....	145
Figure 6.12: Drawings showing cortical pyramidal neurones in the R6/2 model.....	146
Figure 6.13: Drawings showing hippocampal pyramidal neurones in the R6/2 model.....	147
Figure 6.14: Drawings showing Purkinje cells of the <i>cerebellum</i> in the R6/2 model.....	148
Figure 6.15: Drawings showing glial cells in the R6/2 model.....	149
Figure 6.16: Drawings showing mitral cells of the <i>olfactory bulb</i> in the R6/2 model.....	150
Figure 6.17: Graphs of Sholl analyses of the HD94 and R6/1 models at 36 weeks of age.....	151
Figure 6.18: Graphs of dendritic shaft diameters in the HD94 and R6/1 models.....	152
Figure 6.19: Drawings of dendritic branch segments in the HD94 model.....	153
Figure 6.20: Graphs of dendritic spine density in the HD94 and R6/1 models.....	154
Figure 6.21: Graphs of Sholl analysis of the HD80 model.....	157
Figure 6.22: Graphs of dendritic shaft diameters in the HD80 model.....	158
Figure 6.23: Drawings of dendritic branch segments in the HD80 model.....	159
Figure 6.24: Graphs of dendritic spine density in the HD80 model.....	160
Figure 6.25: Summary of Sholl analyses of all models and drawings of R6/2 arbours.....	163
Figure 6.26: Drawings of dendritic arbours of R6/1 & HD94 models.....	164
Figure 6.27: Drawings of dendritic arbours of the HD80 model.....	164
Figure 6.28: Summary graphs of all parameters in R6/2.....	165
Figure 6.29: Summary graph of shaft diameters of all models studied.....	166
Figure 6.30: Summary graph of spine density analyses of all models studied.....	166

Chapter 7: Neuronal Death Processes

Figure 7.1: SEM of healthy and apoptosing HeLa cells.....	168
Figure 7.2: Schematic diagram of apoptosis and necrosis.....	169
Figure 7.3: Drawing of distribution of DCD profiles in anterior cingulate cortex.in R6/2.....	171
Figure 7.4: TEM of DCD in anterior cingulate cortex in 17 week old R6/2.....	172
Figure 7.5: TEM of DCD in anterior cingulate cortex of R6/1 brain.....	174
Figure 7.6: Map & photos showing DCD profiles in R6/2 & R6/1 brain.....	176
Figure 7.7: Schematic maps showing distribution of DCD profiles in R6/2 & R6/1 model....	177
Table 7.1: Table of the incidence of DCD and NIIs in R6/2 model.....	178
Table 7.2: Table of the incidence of DCD and NIIs in R6/1 model.....	179
Figure 7.8: TEM of DCD in cortex of HD94 model.....	181
Figure 7.9: Map & photos showing DCD profiles in HD94 brain.....	182
Figure 7.10: Schematic maps showing distribution of DCD profiles in HD94 model.....	182
Table 7.3: Table of the incidence of DCD and NIIs in HD94 model.....	183
Figure 7.11: TEM showing aspects of DCD in the HD80 model.....	185
Figure 7.12: Map & photos showing DCD profiles in FL HD80 brain.....	187
Figure 7.13: Map & photos showing DCD profiles in Fr HD80 brain.....	188
Figure 7.14: Schematic maps showing distribution of DCD profiles in FL & Fr HD80.....	189
Table 7.4: Table of the incidence of DCD and NIIs in FL & Fr HD80 model.....	189

Chapter 8: Glial Observations

Figure 8.1: Photographs of immunostaining of R6/2 brain for various glial markers.....	196
Figure 8.2: TEM of dying neurones being engulfed by glia in R6/2 model.....	197
Figure 8.3: LM photograph of inclusions in glial cells of R6/2 corpus callosum.....	198
Figure 8.4: TEM of glia in the corpus callosum of R6/2.....	198
Figure 8.5: TEM of NIIs in R6/2 neuroglia.....	199
Figure 8.6: LM photograph of GFAP stained glial cell in HD94 model.....	201
Figure 8.7: Photographs of immunostaining of HD94 brain for various glial markers.....	202
Figure 8.8: LM photograph of htt staining of glia in corpus callosum of HD94 brain.....	203
Figure 8.9: TEM of dying neurones being engulfed by glia in HD94 cortex.....	204
Figure 8.10: Photographs of immunostaining of HD80 brain for various glial markers.....	206
Figure 8.11: Photographs of immunostaining of LMC brain for various glial markers.....	207
Figure 8.9: TEM of dying neurones & glia in HD80 brain.....	208

Chapter 9: Discussion

Figure 9.1: Cartoon of possible foldings of htt protein.....	214
Figure 9.2: EMs of lewy body and fibrillar components in NIL.....	215
Figure 9.3: Hypothesised evolution of the inclusion.....	219
Figure 9.4: Diagram of all the nuclear bodies.....	220
Figure 9.5: Cartoon showing handling of misfolded proteins.....	222
Figure 9.6: Diagram of the UPS.....	223
Figure 9.7: Graphs showing change in body and brain weights in R6/2 model.....	226
Figure 9.8: Diagram of the influence of the mTOR pathway.....	229

Figure 9.9: Graph showing neuronal atrophy in R6/2 model.....	230
Figure 9.10: Diagram explaining sholl and convex hull analyses.....	232
Figure 9.11: Graphs showing dendritic changes in the R6/2 model.....	233
Figure 9.12: Diagram exploring mechanisms of atrophy in R6/2 model.....	234
Figure 9.13: Drawings showing somal areas and spines in R6/2 model.....	235
Figure 9.14: Diagram explaining spine count discrepancy.....	235
Figure 9.15: Graph showing spread of spines over branch orders.....	236
Table 9.1: Table of dendritic spine pathologies.....	238
Figure 9.16: Diagram showing different modes of neuronal cell death.....	241

Chapter 10:Conclusions

Figure 10.1: Graph showing correlation of atrophy and inclusion growth.....	250
--	-----

Appendices

Appendix 2: Summary timeline of the R6/2 model.....	257
Appendix 3 Summary timeline of the R6/1 model.....	258
Appendix 4 Summary timeline of the HD94 model.....	259
Appendix 5 Summary timeline of the HD80 model.....	260



Abbreviations

A

ABC-Avidin-biotin complex

AD-Alzheimer's disease

ALS-Amyotrophic lateral sclerosis

B

BMI-Body mass index

β-Gal-Beta galactosidase, reporter protein from *E.coli*.

C

CAG-Codon coding for glutamine

CBP-Creb binding protein

CJD-Creutzfeld-Jakob disease

CNS-Central nervous system

C57 Black 6-Background strain of mice

D

DAB-Diaminobenzidine

DCD-Dark cell degeneration

DNI-Dystrophic neurite inclusion

DRPLA-dentato-rubra-palado luisian atrophy

E

EM-Electron microscopy / micrograph

ER-Endoplasmic reticulum

F

FL-Full length *Hdh* gene integrated into the HD80 knock-in mouse model

Fr-Fragment of the *Hdh* gene integrated into the HD80 knock-in model

FVB-Background strain of mice sensitive to B strain of Friend Leukaemia virus

G

GABA- γ -Aminobutyric acid

GAD-Glutamic acid decarboxylase

GFAP-Glial fibrillary acidic protein, astrocyte marker.

H

HD-Huntington's disease

HDCRG-Huntington's Disease Collaborative Research Group

HDF-Hereditary Disease Foundation

Hdh-Huntington's disease gene locus

HDSA-Huntington's Disease Society of America

HSP-Heat shock proteins

Htt-Huntingtin protein

L

LM-Light microscopy

LMC-Litter-mate control

LTP-Long-term potentiation

M

MRI-Magnetic resonance imaging

mRNA-Messenger ribonucleic acid

mTOR-Mammalian Target of Rapamycin protein

N

NG2-Integral membrane proteoglycan, marker for immature glia.

NII-Neuronal intranuclear inclusion

P

PD-Parkinson's disease

PDGF α R-Alpha receptor for platelet derived growth factor.

PML-Promyelocytic leukemia

R

RFLP-Restriction fragment linked polymorphism

S

SAHA-suberoylanilide hydroxamic acid

SBMA-Spinobulbar muscular atrophy

SCA-Spinocerebellar ataxia

SOD-Superoxide dismutase

T

TAU-Microtubule associated protein-Tau

TBP-TATA-binding protein

TEM-Transmission electron microscopy / micrograph

TUNEL-Terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labeling

U

Ubq-Ubiquitin

UPS-Ubiquitin proteasome system

Y

YAC-Yeast artificial chromosome